Literature DB >> 24742663

Large personalised medicine trial in lung cancer heralds new research partnership.

Ingrid Torjesen1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24742663     DOI: 10.1136/bmj.g2837

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  4 in total

1.  Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.

Authors:  Angela Hamblin; Sarah Wordsworth; Jilles M Fermont; Suzanne Page; Kulvinder Kaur; Carme Camps; Pamela Kaisaki; Avinash Gupta; Denis Talbot; Mark Middleton; Shirley Henderson; Anthony Cutts; Dimitrios V Vavoulis; Nick Housby; Ian Tomlinson; Jenny C Taylor; Anna Schuh
Journal:  PLoS Med       Date:  2017-02-14       Impact factor: 11.069

2.  Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial data.

Authors:  Marina C Garassino; Massimo Broggini
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

Review 3.  The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research.

Authors:  Donald A Berry
Journal:  Mol Oncol       Date:  2015-03-11       Impact factor: 6.603

4.  pSTAT3 Levels Have Divergent Expression Patterns and Associations with Survival in Squamous Cell Carcinoma and Adenocarcinoma of the Oesophagus.

Authors:  Katie E O' Sullivan; Adriana J Michielsen; Esther O' Regan; Mary C Cathcart; Gillian Moore; Eamon Breen; Ricardo Segurado; John V Reynolds; Joanne Lysaght; Jacintha O' Sullivan
Journal:  Int J Mol Sci       Date:  2018-06-10       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.